NO912864L - Stedsspesifikk in vivo-aktivering av terapeutiske forbindelser - Google Patents

Stedsspesifikk in vivo-aktivering av terapeutiske forbindelser

Info

Publication number
NO912864L
NO912864L NO91912864A NO912864A NO912864L NO 912864 L NO912864 L NO 912864L NO 91912864 A NO91912864 A NO 91912864A NO 912864 A NO912864 A NO 912864A NO 912864 L NO912864 L NO 912864L
Authority
NO
Norway
Prior art keywords
activator
prodrug
target tissue
targeting moiety
vivo activation
Prior art date
Application number
NO91912864A
Other languages
English (en)
Norwegian (no)
Other versions
NO912864D0 (no
Inventor
Reinhard Bredehorst
Chong-Ho Kim
Richard Mccabe
Nicholas Pomato
Carl-Wilhelm Vogel
Original Assignee
Akzo Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23161497&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO912864(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Akzo Nv filed Critical Akzo Nv
Publication of NO912864D0 publication Critical patent/NO912864D0/no
Publication of NO912864L publication Critical patent/NO912864L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6899—Antibody-Directed Enzyme Prodrug Therapy [ADEPT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Nanotechnology (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
NO91912864A 1989-01-23 1991-07-22 Stedsspesifikk in vivo-aktivering av terapeutiske forbindelser NO912864L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30099989A 1989-01-23 1989-01-23
PCT/US1990/000503 WO1990007929A1 (en) 1989-01-23 1990-01-23 Site specific in-vivo activation of therapeutic drugs

Publications (2)

Publication Number Publication Date
NO912864D0 NO912864D0 (no) 1991-07-22
NO912864L true NO912864L (no) 1991-09-19

Family

ID=23161497

Family Applications (1)

Application Number Title Priority Date Filing Date
NO91912864A NO912864L (no) 1989-01-23 1991-07-22 Stedsspesifikk in vivo-aktivering av terapeutiske forbindelser

Country Status (12)

Country Link
EP (1) EP0454783B1 (da)
JP (1) JP3273608B2 (da)
KR (1) KR0185967B1 (da)
AT (1) ATE123414T1 (da)
AU (1) AU648015B2 (da)
CA (1) CA2025899A1 (da)
DE (1) DE69019959T2 (da)
DK (1) DK0454783T3 (da)
ES (1) ES2075893T3 (da)
FI (1) FI97692C (da)
NO (1) NO912864L (da)
WO (1) WO1990007929A1 (da)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5773435A (en) * 1987-08-04 1998-06-30 Bristol-Myers Squibb Company Prodrugs for β-lactamase and uses thereof
US5851527A (en) * 1988-04-18 1998-12-22 Immunomedics, Inc. Method for antibody targeting of therapeutic agents
DK0436717T3 (da) * 1989-08-02 2003-05-05 Mitra Medical Technology Ab System til anvendelse ved en fremgangsmåde til terapeutisk eller diagnostisk behandling
US6610299B1 (en) 1989-10-19 2003-08-26 Aventis Pharma Deutschland Gmbh Glycosyl-etoposide prodrugs, a process for preparation thereof and the use thereof in combination with functionalized tumor-specific enzyme conjugates
DE4106389A1 (de) * 1991-02-28 1992-09-03 Behringwerke Ag Fusionsproteine zur prodrug-aktivierung, ihre herstellung und verwendung
US6475486B1 (en) 1990-10-18 2002-11-05 Aventis Pharma Deutschland Gmbh Glycosyl-etoposide prodrugs, a process for preparation thereof and the use thereof in combination with functionalized tumor-specific enzyme conjugates
US7241595B2 (en) 1989-10-20 2007-07-10 Sanofi-Aventis Pharma Deutschland Gmbh Glycosyl-etoposide prodrugs, a process for preparation thereof and the use thereof in combination with functionalized tumor-specific enzyme conjugates
KR100236375B1 (ko) * 1989-12-11 1999-12-15 오트리브 데이비스 더블유 진단제 또는 치료제를 목표부위에 타게팅하기 위한 제제 및 키트
SE9100142L (sv) 1991-01-17 1992-07-18 Bengt Sandberg En metod och ett system foer foerbaettrad in vivo reducering av diagnostiska och/eller terapeutiska substanser medelst extrakorporeal borttagning, och anvaendandet av naemnda substanser foer detta aendamaal
FR2676058B1 (fr) * 1991-04-30 1994-02-25 Hoechst Lab Prodrogues glycosylees, leur procede de preparation et leur utilisation dans le traitement des cancers.
WO1994001137A1 (en) * 1992-07-06 1994-01-20 Hybritech Incorporated Method for delivery of cytotoxic agents and components thereof
GB9323429D0 (en) * 1993-11-12 1994-01-05 Wellcome Found Therapy
ATE222124T1 (de) * 1994-12-23 2002-08-15 Astrazeneca Ab Chemische mittel
TR199800233T1 (xx) 1995-08-16 1998-06-22 Zeneca Limited Kimyasal bile�ikler.
ES2257756T3 (es) * 1996-03-12 2006-08-01 Sanofi-Aventis Deutschland Gmbh Nuevos profarmacos para la terapia de tumores y enfermedades inflamatorias.
PL229108B1 (pl) * 2014-08-22 2018-06-29 Celther Polska Spolka Z Ograniczona Odpowiedzialnoscia Sposób wydzielania i oczyszczania estrów chityny (mono-, di‑podstawionych) oraz kopoliestrów chityny z mieszanin poreakcyjnych
EP3970752A1 (en) * 2020-09-17 2022-03-23 Merck Patent GmbH Molecules with solubility tag and related methods

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4067774A (en) * 1971-05-14 1978-01-10 Syva Company Compounds for enzyme amplification assay
US4631190A (en) 1981-06-26 1986-12-23 Shen Wei C Acidity-sensitive spacer molecule to control the release of pharmaceuticals from molecular carriers
LU85581A1 (fr) * 1984-10-10 1986-06-11 Smb Lab Ensembles d'anticorps monoclonaux diriges contre la lactoferrine humaine et le lysozyme humain
JPS62138496A (ja) * 1985-12-11 1987-06-22 Ihara Chem Ind Co Ltd キチンオリゴマ−の製造方法
HU213222B (en) * 1987-07-02 1997-03-28 Akzo Nv Method for producing of tumor antigen recognized by monoclonal antibody, antibody directed against antigen anp antibody specific to antiidiotypic antigen
NZ225599A (en) * 1987-08-04 1991-09-25 Bristol Myers Co Antibody-enzyme conjugates and combinations with prodrugs for the treatment of tumour cells
ZA893284B (en) * 1988-05-04 1990-03-28 Igen Inc Peptide analogs and their use as haptens to elicit catalytic antibodies

Also Published As

Publication number Publication date
DK0454783T3 (da) 1995-10-16
EP0454783A4 (en) 1992-01-15
WO1990007929A1 (en) 1990-07-26
EP0454783A1 (en) 1991-11-06
KR910700072A (ko) 1991-03-13
EP0454783B1 (en) 1995-06-07
NO912864D0 (no) 1991-07-22
ES2075893T3 (es) 1995-10-16
FI97692C (fi) 1997-02-10
FI97692B (fi) 1996-10-31
ATE123414T1 (de) 1995-06-15
CA2025899A1 (en) 1990-07-24
FI913511A0 (fi) 1991-07-22
JP3273608B2 (ja) 2002-04-08
AU5039790A (en) 1990-08-13
AU648015B2 (en) 1994-04-14
DE69019959D1 (de) 1995-07-13
DE69019959T2 (de) 1995-10-05
JPH04503068A (ja) 1992-06-04
KR0185967B1 (ko) 1999-05-01

Similar Documents

Publication Publication Date Title
NO912864L (no) Stedsspesifikk in vivo-aktivering av terapeutiske forbindelser
PT740650E (pt) Co-farmacos como um metodo de administracao controlada de farmacos
DK302782A (da) Anvendelse af eucalypol til at foroege et praeparats optagelse gennem huden
DE60026538D1 (de) Pharmazeutische zubereitungen die clavulansäure oder derivate enthalten zur behandlund von neurologischen störungen
DE69232263D1 (de) Radikalfänger ("spin traps") zur behandlung von mit oxidation von lipiden und proteinen verbundenen erkrankungen
GB9710049D0 (en) Method
DE69215722D1 (de) Verstärker zur Ultraschalltherapie von Erkrankungen sowie diesen enthaltende flüssige Arzneimittelzusammensetzungen
EP0681475A4 (en) Therapeutic inhibitors of vascular smooth muscle cells
RU93032613A (ru) Фармацевтический препарат для лечения пациентов с пролонгированным временем коагуляции, способ лечения пациентов, применение epi ингибитора для получения фармацевтического препарата
DK164441C (da) Anvendelse af et piperidinderivat til fremstilling af et farmaceutisk praeparat til behandling af smertetilstande
TR199700711T1 (xx) Ciltten ge�erek v�cuda giren form�lasyon.
ATE334589T1 (de) Anti-arrhythmische zusammensetzungen und behandlungsverfahren
AU5643299A (en) Humic acid and its use in the treatment of various conditions
GR3032224T3 (en) Therapeutic agent for threatened abortion.
Newell Pharmacokinetically guided dose escalation in phase I clinical trials: Commentary and proposed guidelines.
SE8101374L (sv) Kompositioner innehallande n,n-dietyl-m-toluamid
ATE106732T1 (de) Arzneimittelzubereitung, enthaltend stigmasta-4- en-3-on sowie deren verwendung.
NZ503027A (en) Use of rifamycin derivative for treating mastitis in a domestic animal
WO2001007029A3 (en) Substituted guanidines and the use thereof
GB2019720A (en) S-adenosyl-L-homocysteine and salts thereof for use in therapy
FR2700543B1 (fr) Sels de dérivés de 4-pyrimidinone, leur préparation et leur application en thérapeutique.
DK452788D0 (da) Smertestillende praeparat
KR890007737A (ko) 진토작용을 하는 약제
CA2186752A1 (en) Drug treatment of diseased sites deep within the body
UA23921A (uk) Спосіб лікування шлунково-стравохідного рефлюксу